MedTrace Logo

Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer

NCT07166003 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-09-10

No results posted yet for this study

Summary

The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are:

* Does pneumonectomy bring more benefits for pateints than lobectomy?
* Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.

Conditions

  • Lung Cancer, Non-Small Cell
  • Immunotherapy

Interventions

PROCEDURE

Pneumonectomy

Patients will receive pneumonectomy after neoadjuvant treatment

PROCEDURE

lobectomy

Patients will receive lobectomy after neoadjuvant immunotherapy.

RADIATION

radiotherapy

Patients will receive radiotherapy after neoadjuvant immunotherapy.

DRUG

Anti-Tumor Drugs

Patients will receive anti-tumor drugs.

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-20
Primary Completion
2027-02-02
Completion
2030-04-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07166003 on ClinicalTrials.gov